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Abstract
Background: The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution
and improved HIV outcomes. We studied the factors associated with 10 years of continuous VL suppression on HAART
in the US Military HIV Natural History Study.
Methods: Participants with continuous VL suppression (CS, n = 149) were compared to those who did not have
continuous viral load suppression (NCS, n = 127) for ≥10 years on HAART. Factors associated with >10 years of VL
suppression were evaluated by multivariate logistic regression. Additionally, association between CS and CD4
reconstitution was analyzed with a mixed effects model.
Results: Compared to NCS participants, a lower proportion of CS participants started HAART in the early HAART era
(66 vs 90 %, for years 1996–1999; p < 0.001) and had less antiretroviral use prior to HAART (37 vs 83 %; p < 0.001). At
initial HAART, the median CD4 cell count was higher and VL was lower for CS compared to NCS participants (375
cells/uL [256, 499] vs 261 cells/uL [146, 400]; p < 0.001 and 4.4 log10 copies/mL [3.5, 4.9] vs 4.5 log10 copies/mL [3.8, 5.0];
p = 0.048, respectively). New AIDS events were lower during HAART (5 vs 13 %; p = 0.032) and post-HAART CD4
trajectories were greater for the CS compared to NCS group. Factors negatively associated with ≥10 years of VL
suppression included log10 VL at first HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) and antiretroviral use prior to
HAART (OR 0.16, 95 % CI 0.06, 0.38; p < .001).
Conclusions: Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the
lower proportion of AIDS events observed 10 years after HAART initiation. The current use of more potent and
well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by
treatment initiated in the early HAART era.
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Background
The primary goal of highly active antiretroviral therapy
(HAART) in HIV-infected individuals is sustained viral
load (VL) suppression which, in turn, leads to several
benefits. Immune recovery is evidenced by CD4 cell
gains, a reduction in activated CD8 cells, decreased
immune activation, and enhanced responsiveness to
vaccines [1–3]. Effective HAART can also mitigate
opportunistic infections and the development of ac-
quired immunodeficiency syndrome (AIDS) events
[4]. Successful HIV treatment is also associated with
a reduction in HIV-associated non-AIDS diseases, includ-
ing cancer and cardiovascular, renal, and liver disease
[5, 6]. Recent studies have demonstrated life expectancy
approaching that of HIV-uninfected persons for those
with low rates of virologic failure and relatively preserved
CD4 counts [7]. In addition, sustained VL suppression
enhances the durability of the treatment regimen and
prevents the development of antiretroviral resistance [8].
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Unfortunately, not all patients are able to maintain VL
suppression on HAART. In the US, approximately 40 %
of HIV-infected persons have a suppressed VL [9]. Re-
cent cohort studies report VL suppression rates ranging
between 65 and 80 % on a variety of HAART regimens,
whereas newer HAART regimens have suppression rates
approaching 90 % in clinical trials [10–13]. There are
many patient-related and treatment-related factors associ-
ated with virologic failure early in the course of HAART.
Unlike many other chronic conditions, adherence is of
major importance as the probability of VL suppression is
diminished in patients with <95 % adherence [14]. In
addition, suboptimal adherence can lead to increased drug
resistance and reduced quality of life and survival [15, 16].
Sustained VL suppression is essential to achieve the
best possible treatment outcomes. Because a significant
proportion of patients do not achieve this goal, we exam-
ined factors associated with ≥10 years of VL suppression
in the US Military HIV Natural History Study (NHS). We
hypothesize that both patient and treatment-related fac-
tors will be associated with long-term VL suppression,
and analyses included medication adherence and charac-
teristics of the early HAART era such as prior therapy
with single or dual agents. Longitudinal treatment out-
comes spanning the entire HAART era were also analyzed
to evaluate CD4 trajectories and development of new
AIDS events during long-term HAART.
Methods
Study participants
The NHS is a large prospective multicenter cohort of
HIV-infected individuals. The study population is com-
prised of active duty military, retired military, and their
beneficiaries from the Army, Navy/Marines, and Air
Force. Participants are evaluated approximately every 6–
12 months at military treatment facilities throughout the
United States. Data between study visits are systematically
collected, including demographic characteristics, labora-
tory data, information on medication use, and reports of
clinical events with medical record confirmation. The
NHS has been enrolling since 1986 and consists of more
than 5800 participants. Self-reported adherence (SRA)
data has been systematically collected since 2006. All par-
ticipants provided informed written consent and this
study protocol was approved by the Uniformed Services
University of the Health Sciences central IRB.
Inclusion criteria
NHS participants initiating HAART on or after January
1, 1996 with ≥10 years of continuous treatment were
included. Participants were required to have ≥1 VL and
CD4 count determinations per year during follow-up, with
data collected through December 31, 2013. Treatment
interruptions <6 months in duration were permitted.
HAART was defined as two or more nucleoside reverse
transcriptase inhibitors (NRTIs) in combination with at
least one protease inhibitor (PI), one nonnucleoside re-
verse transcriptase inhibitor (NNRTI), or one integrase
strand transfer inhibitor (INSTI). Regimens comprised of
one NRTI with at least one PI and one NNRTI or an aba-
cavir or tenofovir containing regimen of 3 or more NRTIs
in the absence of both PIs and NNRTIs were also consid-
ered HAART. Non-HAART antiretroviral (ARV) use was
defined as treatment not meeting HAART criteria above
and typically consisted of mono- or dual-therapy prior to
the availability of HAART. The total number of HAART
regimens, defined as changes to any or all ARV compo-
nents, were also captured during the study period.
VL suppression was defined as achieving a VL ≤400
copies/mL within the first year of HAART. Virologic
failure was defined as not achieving suppression or two
consecutive VL determinations ≥400 copies/mL after ini-
tial suppression. The threshold of 400 copies/mL was
chosen in order to compare outcomes during the entire
HAART era given the differences in VL assay detection
limits over time. Participants were divided into two sep-
arate groups for analysis. The continuous VL suppres-
sion (CS) group was defined as those with all VL values
≤400 copies/mL for ≥10 years. The non-continuous VL
suppression (NCS) group was defined as having 1 or
more episodes of virologic failure during the study
period. Since more sensitive VL assays with limits of de-
tection <50 copies/mL became clinically available during
the later HAART era, we also analyzed the proportion
with VL suppression <50 copies/mL in both groups.
CD4 count trajectories and development of AIDS events
after HAART initiation were also analyzed. SRA data
was obtained via voluntary participant questionnaire
with adherence defined by the overall percentage of
HAART doses taken in the prior 6 months.
Statistical analysis
Cohort demographics and other characteristics associ-
ated with HIV were described separately for participants
in the CS and NCS groups. For continuous variables,
t-tests were used for normally distributed variables or
by Wilcoxon tests when appropriate. For categorical
variables, chi-squared tests or Fisher’s exact tests were
used. From the clinically relevant baseline characteristics,
logistic regression was used to analyze the impact of
factors on continuous VL suppression during 10 years
of HAART. SRA data was calculated as the average
and minimum percent adherence and evaluated by t-
tests. Adherence was also evaluated as a categorical
variable (report of 100 % adherence yes/no) and analyzed
by chi-squared test.
Mixed effects models were used to analyze the factors
associated with longitudinal CD4 cell reconstitution.
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The square root of the CD4 count was used to normalize
the data. An interaction term between the years from
HAART initiation to VL suppression was used to quantify
the difference in the rate of CD4 cell increase between
groups. From this data subset, a locally-weighted scatter
plot smoothing (LOWESS) was created to visualize trends
in CD4 cell reconstitution over 10 years on HAART.
Results
A total of 276 participants met the inclusion criteria
(Table 1). Participants were predominately male with
similar proportions of Caucasians and African Americans
in each group. The median age at HIV diagnosis was
32 and 30 years in the CS and NCS groups, respectively
(p = 0.065). A greater proportion of NCS participants
(90 %) were treated in the early HAART era (1996–1999)
compared with the CS group (66 %; p < 0.001). The me-
dian CD4 count at first HAART was higher in the CS
compared with the NCS group (375 vs 261 cells/uL;
p < 0.001) and the median VL at first HAART was 4.4
log10 copies/mL and 4.5 log10 copies/mL, respectively
(p = 0.048). First HAART regimens differed among the
groups (p < 0.001), with NCS having a higher proportion
of unboosted PI use compared with CS participants (76 %
vs 51 %). AIDS outcomes prior to first HAART were simi-
lar for CS (8 %) and NCS participants (12 %; p = 0.399).
During longitudinal follow-up, groups had a median of 1
treatment interruption [0,1], with a higher proportion of
any treatment interruption observed in NCS (57 %) com-
pared to CS (17 %) participants (p < 0.001). NCS partici-
pants also had a greater median number of HAART
regimens (7 [4, 9] vs 3 [2, 5]; p < .001) and a higher
proportion of new AIDS events by 10 years of HAART
(13 vs 5 %; p = 0.032) compared with CS participants.
In a subgroup analysis of participants with VL data
using assays with a limit of detection <50 copies/mL
Table 1 Baseline Characteristics of Participants
Characteristic All Continuous VL suppression Non-continuous VL suppression P-value
Number of participants, n 276 149 127 –
Gender, Male 252 (91 %) 137 (92 %) 115 (91 %) 0.845
Race – – – 0.234
Caucasian 119 (43 %) 70 (47 %) 49 (39 %) –
African-American 126 (46 %) 61 (41 %) 65 (51 %) –
Hispanic/Other 31 (11 %) 18 (12 %) 13 (10 %) –





Median Age at HIV Diagnosis, years 31 (26,38) 32 (28,38) 30 (25, 37) 0.065
Median Year of HAART Initiation 1997 (1996,1999) 1998 (1997,2001) 1997 (1996,1998) <0.001
HAART Era at Initiation – – – <0.001
1996–1999 212 (77 %) 98 (66 %) 114 (90 %) –
2000–2003 64 (23 %) 51 (34 %) 13 (10 %) –
Median Age at First HAART, years 37 (32,42) 37 (32,41) 37 (31,42) 0.807







Median VL at first HAART, log10 copies/mL 4.5 (3.6,4.9) 4.4 (3.5, 4.9) 4.5 (3.8, 5) 0.048
AIDS before first HAART 27 (10 %) 12 (8 %) 15 (12 %) 0.399
First HAART Regimen – – – <0.001
3 NRTI 14 (5 %) 12 (8 %) 2 (2 %) –
Boosted PI 20 (7 %) 7 (5 %) 13 (10 %) –
NNRTI 53 (19 %) 43 (29 %) 10 (8 %) –
PI + NNRTI + NRTI 16 (6 %) 11 (7 %) 5 (4 %) –
Unboosted PI 173 (63 %) 76 (51 %) 97 (76 %) –
Non-HAART ARV Use Before HAART 160 (58 %) 55 (37 %) 105 (83 %) <0.001
History of HBV Infection Before First HAART 125 (45 %) 60 (40 %) 65 (51 %) 0.090
History of HCV Infection Before First HAART 12 (4 %) 5 (3 %) 7 (6 %) 0.562
Abbreviations: HAART highly active antiretroviral therapy, VL viral load, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitor, NNRTI non-nucleoside
reverse transcriptase inhibitor, HBV hepatitis B virus, HCV hepatitis C virus, ARV antiretroviral
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during HAART, the proportion with a suppressed VL
<50 copies/mL was higher in the CS group (2399 of
2550 VL values, 94 %) compared to the NCS group
(1545 of 2221, 70 %; p < 0.001).
Self-reported adherence
SRA was high in both groups (Fig. 1), with an average
SRA of 99 % in the CS group and 98 % in the NCS
group (p = 0.341). A similar proportion of participants
reported always having 100 % adherence in the CS
(26 %) and NCS (24 %; p = 0.727) groups.
Factors associated with VL suppression
Analysis of demographic factors showed no association
between age at first HAART and VL suppression for
≥10 years (Odds ratio [OR] 1.0 per 10 years, 95 % confi-
dence interval [CI] 0.68, 1.47; p = 0.984, Table 2). The
use of non-HAART ARVs prior to first HAART (OR
0.16, 95 % CI 0.06, 0.38; p < 0.001) and log10 VL at first
HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) were
both negatively associated with ≥10 years of VL suppres-
sion. A negative trend for long-term VL suppression was
observed for African Americans compared with Cauca-
sians, but this association was marginal (OR 0.53, 95 %
CI 0.25, 1.07; p = 0.079). No association was observed
for the time from HIV diagnosis to first HAART, CD4
count at first HAART, or type of first HAART regimen.
For factors after initiation of first HAART, the total
number of HAART regimens used during the study
period was negatively associated with long-term VL sup-
pression (OR 0.71, 95 % CI 0.6, 0.81; p < 0.001) due to
virologic failures, while no association was observed for
SRA (OR 0.82, 95 % CI 0.39, 1.73 for those always
reporting 100 % adherence; p = 0.607).
CD4 cell reconstitution on HAART
Longitudinal CD4 cell trends during the first 10 years of
HAART showed that the CS group had a greater upward
trajectory of CD4 cell gains compared with the NCS
group (Fig. 2). Analysis of factors associated with the
change in CD4 count from first HAART initiation to
10 years after beginning HAART showed a negative
adjusted difference in square root of CD4 (√CD4) for ARV
use prior to first HAART (−1.73, 95 % CI−3.44,−0.02; p =
0.047), longer time from HIV diagnosis to first HAART
(−0.02, 95 % CI−0.03, 0; p = 0.025), and higher log10 VL at
Fig. 1 Self-reported Adherence




Age at First HAART, per 10 years 1.0 (0.68, 1.47) 0.984
Race (Ref: Caucasian)
African-American 0.53 (0.25, 1.07) 0.079
Hispanic/Other 0.51 (0.19, 1.42) 0.194
CD4 Count at First HAART, per 50 cells/uL 1.08 (0.99,1.19) 0.112
Log10 VL at First HAART 0.61 (0.4, 0.92) 0.02
HAART Regimen (Ref: NRTI)
Boosted PI 0.8 (0.08, 6.1) 0.841
NNRTI 1.59 (0.18, 9.31) 0.630
PI + NNRTI + NRTI 1.47 (0.15, 11.04) 0.716
Unboosted PI 0.67 (0.08, 3.31) 0.651
Non-HAART ARV Use Prior to HAART 0.16 (0.06, 0.38) <0.001
Time from HIV Diagnosis to First HAART,
months
1.00 (0.99, 1.01) 0.664
Total number of HAART Regimens 0.71 (0.6, 0.81) <0.001
Self-Reported Adherence Always 100 % 0.82 (0.39, 1.73) 0.607
Fig. 2 Lowess Curves for CD4 Count Trajectories After
HAART Initiation
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first HAART (−1.7, 95 % CI−2.36,−1.03; p < 0.001; Table 3).
Continuous VL suppression was associated with greater
adjusted difference in √CD4 at baseline (2.3, 95 % CI 0.8,
3.81; p = 0.003) and marginal rate of increase in √CD4
during follow-up (0.13 95 % CI 0, 0.26; p = 0.049),
whereas no association was observed for demographic
factors and SRA.
Discussion
Over the past 20 years, the availability of HAART has
effectively transformed HIV from a uniformly fatal
condition to that of a chronic disease. Contemporary
treatment is associated with improved life expectancy,
with one study finding no elevated mortality risk in pa-
tients with CD4 counts above 500 cells/uL who maintained
VL suppression [17]. Since long-term VL suppression is
required for optimal HIV disease outcomes, we aimed to
determine the factors associated with sustained virologic
control on HAART in a large military cohort.
The inability of many patients to maintain VL sup-
pression can be explained in part by the era in which
participants began HAART. A previous study in our co-
hort reported VL suppression during the early HAART
era (1996–2000) compared to the late HAART era
(2000–2007), with 58 and 85 % VL suppression at 5 years
for those treated in the early versus late HAART era, re-
spectively [10]. Similarly, the Antiretroviral Therapy
(ART) Cohort Collaboration analyzed treatment naïve
participants who began HAART from 1995 to 2003 and
observed an increase in VL suppression in later years, with
58 and 83 % for those initiating HAART between 1995–
1996 and 2002–2003, respectively [18]. Our current study
with a longer duration of follow-up after HAART initi-
ation (≥10 years) affirms that treatment during the early
HAART era is a risk for non-continuous VL suppression.
The use of ARVs prior to HAART, typically mono- or
dual-therapy, is an important characteristic of the early
HAART era. We observed that ARV use prior to
HAART negatively impacted both the ability to achieve
long-term VL suppression and the magnitude of CD4
cell gains during HAART. Although non-HAART ARV
use was likely a major reason for suboptimal treatment
outcomes, other features of the early HAART era other
factors likely contributed to the lower rate of treatment
success during that period. For example, the early
HAART era is also characterized by less potent,
unboosted PI regimens, which were more commonly
used for first HAART in the NCS group, and other
HAART regimens associated with greater adverse effects
and reduced tolerability compared to more contempor-
ary regimens [19, 20]. In contrast to the beginnings of
HAART, continuous VL suppression is more attainable
with newer HAART regimens. For example, recent studies
of integrase inhibitor-based regimens have demonstrated
VL suppression in approximately 87 % of treatment
naïve patients [21, 22]. However, longer follow-up
time is necessary to determine the long-term durability of
newer regimens.
Advanced HIV disease, as evidenced by low CD4 cell
count and AIDS events, is associated with lower rates of
VL suppression on HAART [19, 23, 24]. In our current
study, we observed that new AIDS events occurring
during HAART were more common in those with non-
continuous VL suppression despite long-term treatment.
We previously found that high cumulative VL on HAART
was associated with a greater than 2-fold increase in AIDS
events and impacted overall CD4 gains [11]. In our
current study, the trajectory of CD4 cells gains over a 10-
year period was much higher in those with continuous VL
suppression. This is consistent with other studies showing
maximal CD4 reconstitution occurs with sustained VL
suppression [25, 26]. Thus, the long-term maintenance of
VL suppression is of key importance for achieving optimal
immune recovery and for the reduction of AIDS events.
Suboptimal treatment outcomes involve both clinical
and non-clinical factors. For example, access and en-
gagement in care have been identified as key areas along
the HIV care continuum [9]. Some of these barriers are
minimized or removed in the NHS cohort as military
members and beneficiaries have free access to care and
prescription medications. These benefits were demon-
strated in a previous NHS study demonstrating a high
Table 3 Factors Associated with Differences in CD4 Count from
First HAART to 10 Years
Factor Adjusted difference in √CD4 from
first HAART to 10 years (√cells/uL)
P-value
Age at First HAART, per
10 years
−0.38 (−1.06, 0.3) 0.273
Race (Ref: Caucasian) Reference group: Caucasian –
African-American 0.19 (−1.06, 1.45) 0.765
Hispanic/Other 0.82 (−1.21, 2.85) 0.429
Log10 VL at First HAART −1.7 (−2.36, −1.03) <0.001
HAART Regimen (Ref: NRTI)
Boosted PI 0.23 (−3.25, 3.72) 0.895
NNRTI 0.71 (−2.2, 3.62) 0.631
PI + NNRTI + NRTI 0.27 (−3.39, 3.94) 0.883
Unboosted PI 1.49 (−1.28, 4.26) 0.290
Non-HAART ARV Use Prior
to HAART
−1.73 (−3.44, −0.02) 0.047
Time from HIV Diagnosis to
First HAART, months
−0.02 (−0.03, 0) 0.025
100 % Med Adherence 0.53 (−0.84, 1.91) 0.445
Continuous VL Suppression 2.3 (0.8, 3.81) 0.003
Rate of Increase for
Continuous VL Suppression
0.13 (0,0.26) 0.049
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proportion of VL suppression (81 %) at 1 year [10]. Recent
studies in other healthcare settings report slightly lower
VL suppression ranging from 70 to 78 %, which may be
contributed by access to care or patient characteristics
such as injection drug use or socioeconomic factors not
typically present in the military population [27–29].
Discordant HIV treatment outcomes have been ob-
served in different racial/ethnic groups. A study of non-
white participants found a VL suppression rate of 31 %
compared to 54 % in white participants at 7–14 months in
an urban setting [23]. Non-white ethnicity was also linked
to higher number of missed appointments, injection drug
use, and lower CD4 count at HAART initiation [23]. A
previous study in our cohort showed that African Ameri-
cans had lower odds of VL suppression at 6 and 12 months
post-compared to participants of European ancestry,
although time to virologic failure was no different once
suppression was achieved [30]. Similarly, a negative trend
for ≥10 years of VL suppression was also observed in
African Americans in our current study, however only
a small subset of the NHS cohort was included and
additional studies are needed to evaluate potential dif-
ferences according to race/ethnicity.
Adherence is a cornerstone of successful HIV treatment.
We found no difference in those reporting 100 % SRA in
CS and NCS participants and the overall adherence was
98 % or greater in both groups. This high degree of SRA
may be somewhat explained by free access to care and
medications, or possibly by other characteristics of our
population such as level of education, socioeconomic sta-
tus, or very low rate of injection drug use [31]. Other ex-
planations may include potential disadvantages of SRA
compared with other methods to assess adherence. For
example, SRA is subject to recall and social desirability
bias and patients tend to report a 10–20 % over estimation
on adherence when directly compared to data obtained
from electronic drug monitoring [32]. Methods such as
medication event monitoring system (MEMS) track caps
can be more accurate as they report exact date and times
of all bottles opening. One study found that high MEMS
adherence rates, but not high SRA, was associated with
VL suppression [33]. However, MEMS has potential
drawbacks of cost and tracking does not always directly
correlate with pill ingestion [34].
The strengths of this study include long-term follow-
up spanning the entire HAART era in a diverse cohort
of patients with free access to care and medications.
Limitations included the inability to assess adherence in
the early HAART era since SRA data was not systemat-
ically captured until 2006. The high level of SRA in our
study likely limited the ability to detect an association
between adherence and VL suppression, since >95 %
adherence is associated with optimal and sustained VL
suppression [14]. However, equally high SRA in both
groups allowed for the evaluation of other factors associ-
ated with ≥10 years of VL suppression in our cohort.
Other potential study limitations include the retrospective
study design and non-randomized treatment decisions.
Differing limits of detection of VL assays used during the
18-year study period, particularly in the early HAART era,
may have limited the interpretation of factors associated
with continuous viral load suppression. Our results may
not be generalizable to women, given the high proportion
of males in our cohort, or to populations with other
characteristics such as injection drug use.
Conclusion
Sustained VL suppression is essential to reduce long-term
morbidity in HIV-infected patients, as demonstrated by
the lower proportion of AIDS events and improved CD4
cell reconstitution after ≥10 years of continuous VL sup-
pression. We identified factors negatively associated with
≥10 years of VL suppression, including high VL at first
HAART, prior ARV use, HIV diagnosis in the pre-
HAART era, and number of HAART regimens used. It is
likely that treatment in the current era, characterized by
regimens that are more potent, more convenient, and less
toxic, may promote higher success rates and more durable
VL suppression in the future.
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